No Data
No Data
Aligos Therapeutics Collaborating With Xiamen Amoytop Biotech in China for Chronic Hepatitis B Patients
Insiders Were the Biggest Winners as Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) Market Cap Grew by CN¥1.6b Last Week
Amoytop Biotech Gets China Nod to Test Thrombocythemia Drug
Xiamen Amoytop Biotech (688278.SH): Director Lan Chun plans to reduce a total of no more than 380,000 shares of the company's shareholding.
Xiamen Amoytop Biotech (688278.SH) announced on June 14 that Mr. Lan Chun, a director, plans to reduce his shareholding by no more than 380,000 shares in the company through block trading and bulk trading methods due to personal funding needs. The proportion of the company's total share capital will not exceed 0.093%, and the proportion of the number of shares held by himself before the reduction will not exceed 25%. During the reduction period, the price of the reduction will be determined based on the market price during the implementation period.
Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Tebao Biotech (688278.SH): Currently, the company's main business products are mainly domestic sales
Gelonghui, May 23丨Tebao Biotech (688278.SH) recently said during a survey reception from institutional investors that currently the company's main business products are mainly domestic sales, accounting for 0.19% of overseas sales revenue in 2023. Some of the company's products have been approved for registration in some overseas countries, and in the future, the company will further expand its international business according to business conditions.
No Data